Week of March 1, 2025: Suzetrigine’s promise, HIPAA rules and exemptions, and no-show fixes

From breakthrough treatments to evolving regulations, healthcare is constantly changing — and we’re here to help you stay ahead.

This week, we take a closer look at Suzetrigine, a new painkiller stirring up debate over its "nonaddictive" claims. Plus, we break down surprising Health Insurance Portability and Accountability Act (HIPAA) exemptions, HIPAA-compliant marketing strategies, and best practices for patient privacy. Finally, discover how to tackle patient no-shows and cancellations through online scheduling, a calculation rate, and other innovative solutions.

Suzetrigine, a new painkiller marketed as nonaddictive, has sparked widespread curiosity and debate. As the first treatment of its kind, it offers a potential alternative to opioids, a class of drugs that has caused devastating addiction rates. 

To understand the perspectives surrounding Suzetrigine, Tebra surveyed healthcare professionals and patients. Find out why providers and patients are cautiously optimistic about Suzetrigine's potential — and what their top questions are that need to be addressed before widespread adoption.

Thank you for reading The Intake. As always, if you have questions or suggestions for future topics, please don't hesitate to drop a line at [email protected].